Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iodine-123-labelled nor-β-CIT is a radioiodinated analogue of cocaine designed as a radiotracer for single-photon emission computed tomography (SPECT) imaging of monoamine transporter sites in the brain. It binds with high affinity to the serotonin transporter (SERT) and also displays significant binding to dopamine transporters (DAT), with regions of maximal uptake associated with transporter-rich brain areas such as the striatum (DAT) and midbrain (SERT). Its mechanism exploits specific transporter affinities to visualize serotonergic and dopaminergic projections in vivo. It is used primarily as a research radiopharmaceutical for imaging and quantification of serotonin and dopamine transporter densities in neurological diseases such as Parkinson's disease and certain psychiatric conditions[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iodine-123-labelled nor-β-CIT.